Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy
Sukbin Jang, Ji-Young Rhee
Abstract
No effective treatment for COVID-19 has been well established yet. Nafamostat, known as anticoagulant, has potential anti-inflammatory and anti-viral activities against COVID-19. We report three cases of COVID-19 pneumonia who progressed while using antiviral drugs and needed supplementary oxygen therapy, improved after treatment with nafamostat. These preliminary findings show the possibility that Nafamostat can be considered to be used in elderly patients with COVID-19 pneumonia who need oxygen therapy. The effectiveness of nafamostat should be evaluated in further studies.
Topics & Concepts
PneumoniaCoronavirus disease 2019 (COVID-19)MedicineOxygen therapyIntensive care medicineAnticoagulant therapy2019-20 coronavirus outbreakViral pneumoniaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineVirologyDiseaseInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Pharmacological Receptor Mechanisms and Effects